Literature DB >> 33322336

Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells.

Dusana Majera1, Martin Mistrik1.   

Abstract

Survivin, as an antiapoptotic protein often overexpressed in cancer cells, is a logical target for potential cancer treatment. By overexpressing survivin, cancer cells can avoid apoptotic cell death and often become resistant to treatments, representing a significant obstacle in modern oncology. A survivin suppressor, an imidazolium-based compound known as YM-155, is nowadays studied as an attractive anticancer agent. Although survivin suppression by YM-155 is evident, researchers started to report that YM-155 is also an inducer of DNA damage introducing yet another anticancer mechanism of this drug. Moreover, the concentrations of YM-155 for DNA damage induction seems to be far lower than those needed for survivin inhibition. Understanding the molecular mechanism of action of YM-155 is of vital importance for modern personalized medicine involving the selection of responsive patients and possible treatment combinations. This review focuses mainly on the documented effects of YM-155 on DNA damage signaling pathways. It summarizes up to date literature, and it outlines the molecular mechanism of YM-155 action in the context of the DNA damage field.

Entities:  

Keywords:  DNA damage; YM-155; molecular mechanism of action; survivin

Mesh:

Substances:

Year:  2020        PMID: 33322336      PMCID: PMC7763167          DOI: 10.3390/ijms21249431

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   6.208


  71 in total

Review 1.  IAP family proteins--suppressors of apoptosis.

Authors:  Q L Deveraux; J C Reed
Journal:  Genes Dev       Date:  1999-02-01       Impact factor: 11.361

Review 2.  Autophagy as a target for anticancer therapy.

Authors:  Filip Janku; David J McConkey; David S Hong; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2011-05-17       Impact factor: 66.675

3.  Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

Authors:  T Iwasa; I Okamoto; K Takezawa; K Yamanaka; T Nakahara; A Kita; H Koutoku; M Sasamata; E Hatashita; Y Yamada; K Kuwata; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 9.075

Review 4.  GammaH2AX and cancer.

Authors:  William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier
Journal:  Nat Rev Cancer       Date:  2008-11-13       Impact factor: 60.716

5.  Cancer drug's survivin suppression called into question.

Authors:  David Holmes
Journal:  Nat Med       Date:  2012-06-06       Impact factor: 87.241

6.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Authors:  Takahito Nakahara; Aya Kita; Kentaro Yamanaka; Masamichi Mori; Nobuaki Amino; Masahiro Takeuchi; Fumiko Tominaga; Shinji Hatakeyama; Isao Kinoyama; Akira Matsuhisa; Masafumi Kudoh; Masao Sasamata
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 13.312

7.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Authors:  Anthony W Tolcher; Alain Mita; Lionel D Lewis; Christopher R Garrett; Elizabeth Till; Adil I Daud; Amita Patnaik; Kyri Papadopoulos; Chris Takimoto; Pamela Bartels; Anne Keating; Scott Antonia
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 50.717

8.  YM155 induces apoptosis in p53-deficient T-acute lymphoblastic leukemia cells independent of survivin inhibition.

Authors:  Leilane Sales; Graziella R de Sousa; Guilherme Á Ferreira-Silva; Angel M Castro-Gamero; Marisa Ionta; Jaqueline C de Oliveira
Journal:  Anticancer Drugs       Date:  2017-03       Impact factor: 2.389

9.  YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.

Authors:  Roser Mir; Elisabetta Stanzani; Fina Martinez-Soler; Alberto Villanueva; August Vidal; Enric Condom; Jordi Ponce; Joan Gil; Avelina Tortosa; Pepita Giménez-Bonafé
Journal:  Gynecol Oncol       Date:  2013-11-19       Impact factor: 5.304

10.  Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.

Authors:  Dusana Majera; Zdenek Skrott; Katarina Chroma; Joanna Maria Merchut-Maya; Martin Mistrik; Jiri Bartek
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

View more
  1 in total

1.  Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.

Authors:  Qinqin Xu; Ryan P Mackay; Adam Y Xiao; John A Copland; Paul M Weinberger
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.